Omeprazol Tarbis (Omeprazole)

Omeprazole, the active ingredient in Omeprazol Tarbis, is a proton pump inhibitor presented as a 20 mg tablet for oral use. It reduces stomach acid production and is used to treat acid‑related gastrointestinal conditions in adults and children.

GNH USA supplies Omeprazol Tarbis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole acts on the gastric proton pump to manage disorders characterised by excess acid secretion. - Gastro‑esophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis. - Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence. - Zollinger‑Ellison syndrome: controls gastric acid hypersecretion associated with gastrin‑producing tumours.

Adverse reactions to omeprazole are generally mild and dose‑dependent.

Common Side Effects: - Headache: mild, transient headache reported in clinical studies. - Diarrhea: loose stools occurring in a minority of patients. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach region. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis linked to altered gut flora. - Acute interstitial nephritis: sudden kidney inflammation. - Stevens‑Johnson syndrome: rare severe skin reaction. - Hypersensitivity reactions: rash, angio‑edema or anaphylaxis. - Low magnesium levels (hypomagnesemia): may cause muscle cramps or cardiac arrhythmia. - Fracture risk: increased incidence of hip, wrist or vertebral fractures with long‑term use.

When prescribing omeprazole, clinicians should consider several safety aspects. - Assess renal function: adjust use in patients with severe renal impairment. - Review concomitant medications: evaluate for potential drug‑drug interactions. - Monitor long‑term therapy: periodic assessment of bone health and magnesium levels is advised. - Use during pregnancy: weigh benefits against potential risks; limited data are available. - Use in lactating women: small amounts are excreted in breast milk; clinical judgment required. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Omeprazole may interact with several medicines that share metabolic pathways or depend on gastric pH.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect due to CYP2C19 inhibition. - Atazanavir: decreased absorption of the antiviral due to increased gastric pH. - Methotrexate: increased serum levels and toxicity risk.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of INR values. - Phenytoin: possible reduction in phenytoin plasma concentrations. - Digoxin: modest increase in digoxin levels. - Ketoconazole: reduced antifungal absorption. - Iron supplements: diminished iron uptake when taken simultaneously.